EISAI AHEAD 3-45 BAN2401-G000-303 (Phase 3)

Back to Drug Development Trials
Drug Development Trials

About the trial

WA only

This is a Phase 3 study to test whether treatment with BAN2401, an anti-amyloid monoclonal antibody, prevents cognitive decline and reduces brain amyloid accumulation. The changes in the amount of amyloid by PET scans and tau in the brain will be monitored to determine the efficacy of the investigational medication.

Who can be involved:

  • Male or female, aged 55 – 80 years inclusive, at the time of informed consent
  • Must have risk factors for Alzheimer’s disease (first-degree relative but no formal diagnosis)
  • Have an identified, reliable, study partner
  • If using medications to treat symptoms related to Alzheimer’s disease, doses must be stable for at least 3 months before screening

What is involved:

  • Fortnightly / monthly visits
  • 5 years trial duration
  • Fortnightly / monthly IV infusion (fortnightly or monthly depending on your risk of Alzheimer’s disease)
  • Must be able to tolerate MRI and PET scans
  • 50% chance of receiving a placebo

Additional info:

For further information please contact Paula Mather, Clinical Trial Coordinator at Ph: (08) 9389 6433 or Email: aarfctd@alzheimers.com.au

* Please note that participants in this study may have a chance of being placed on placebo medication.